CynergisTek (CTEK) Upgraded to Buy by Zacks Investment Research
CynergisTek (NYSEAMERICAN:CTEK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm currently has a $5.25 target price on the stock. Zacks Investment Research‘s price target points to a potential upside of 10.99% from the company’s current price.
According to Zacks, “CynergisTek, Inc. provides cyber security and information management consulting in healthcare industry. It specializes in privacy, security, compliance and document management. The company’s service includes risk assessment, technical security, baseline security, information security program assessment, print security, vulnerability, architecture, penetration testing, social engineering and phishing and riskSonar assessment tool. CynergisTek Inc., formerly known as Auxilio, Inc., is headquartered in Mission Viejo, CA. “
CTEK stock traded down $0.03 during midday trading on Thursday, reaching $4.73. 7,000 shares of the company’s stock traded hands, compared to its average volume of 13,133. CynergisTek has a 52 week low of $3.23 and a 52 week high of $5.45.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE bought a new stake in shares of CynergisTek in the 2nd quarter worth $2,298,000. ARS Investment Partners LLC grew its stake in shares of CynergisTek by 40.4% in the 3rd quarter. ARS Investment Partners LLC now owns 463,180 shares of the company’s stock worth $1,783,000 after acquiring an additional 133,362 shares in the last quarter. Bridgeway Capital Management Inc. grew its stake in shares of CynergisTek by 50.5% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 164,000 shares of the company’s stock worth $631,000 after acquiring an additional 55,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of CynergisTek by 30.2% in the 3rd quarter. Vanguard Group Inc. now owns 98,036 shares of the company’s stock worth $377,000 after acquiring an additional 22,722 shares in the last quarter. Finally, Vanguard Group Inc grew its stake in shares of CynergisTek by 30.2% in the 3rd quarter. Vanguard Group Inc now owns 98,036 shares of the company’s stock worth $377,000 after acquiring an additional 22,722 shares in the last quarter.
Cynergistek, Inc provides outsourced document solutions, IT consulting data security, and managed print services primarily to the healthcare industry in the United States. The company offers Incident Response, Vendor Security Management, and Patient Privacy Monitoring Service, as well as Compliance Assist Partner Program.
Further Reading: Stop Order
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CynergisTek Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CynergisTek and related companies with MarketBeat.com's FREE daily email newsletter.